Search results
Actavis Generics (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial ...
Aug 2, 2016 · Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Allergan plc (NYSE: AGN) today announced that Teva has completed its acquisition of Allergan’s generics business (“Actavis Generics”). This strategic acquisition brings together two leading generics businesses with complementary strengths, R&D capabilities, product pipelines ...
Feb 18, 2014 · Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction - Creates an Innovative New Model in Specialty Pharmaceuticals Leadership, with $15 Billion...
Jul 27, 2016 · Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) (TASE:TEVA) and Allergan plc (NYSE:AGN) today announced that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with the pending acquisition of Allergan’s generics business (“Actavis Generics”) by Teva Pharmaceutical Industries Ltd.
Feb 18, 2014 · Generic drug giant Actavis (ACT) agreed to buy Forest Laboratories for $25 billion in cash and stock Tuesday, making for the biggest deal yet in specialty pharma's recent consolidation boom.
Teva’s recent Actavis acquisition proves there is strategic power in smart mergers. A thoughtful acquisition that introduces new capabilities and global efficiencies can create the foundation for positive growth for a pharmaceutical company, while also benefiting the patients it serves.
Oct 29, 2015 · Teva agreed in July to pay $40.5 billion - $33.75 billion in cash and $6.75 billion in stock - for Allergan's Actavis generics business. Teva will also sell $22 billion of bonds, mostly dollars ...
